logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
21/05/2025
JPMorgan Chase gives Bubble Mart an initial rating of super match, with a target price of HK$250, an increase of 20%.
Latest
4 m ago
1800 yuan per month: Google releases AI packaging for the whole family - Google AI Ultra
4 m ago
Google announced the release of AI Ultra at the "I/O 2025" global developers conference early this morning. Google AI Ultra integrates the company's best models, various advanced functionalities, and 30T of cloud storage to help professionals in industries such as film, finance, and healthcare improve work efficiency and save time through AI. With such powerful features, the monthly fee is $249.99 (approximately 1809 yuan), which is $50 more expensive than ChatGPT Pro. Users of AI Ultra can experience the highest version of the Gemini app, which sets the highest usage limit in the field of deep research and supports video generation with Veo 2. It also allows users to access the groundbreaking Veo 3 model early, which is ideal for programming, academic research, and complex creative work. In the coming weeks, Ultra subscribers will be able to use the new enhanced reasoning mode Deep Think 2.5 Pro. (AIGC Open Community).
5 m ago
The NASDAQ biotechnology index closed up 1.55%. Akero Therapeutics rose 22.71%, Sana Biotechnology rose 22.02%, and 89bio rose 20.97% ranking third. Among the COVID-19 vaccine concept stocks, CureVac NV ADR rose 10.47% and Moderna rose 6.31%, performing well. Anavex Life Sciences fell 9.95%, ranking third from the bottom, while Prime Medicine fell 15.01% and Alumis fell 16.89%.
5 m ago
The NASDAQ Biotechnology Index closed up 1.55%. Component stocks Akero Therapeutics rose 22.71%, Sana Biotechnology rose 22.02%, and 89bio rose 20.97%. In terms of performance, CureVac NV ADR, a third-generation COVID-19 vaccine concept stock, rose 10.47%, and Moderna rose 6.31%. Anavex Life Sciences closed down 9.95%, ranking third from last, and Prime Medicine fell 15.01% while Alumis fell 16.89%.
6 m ago
CureVac (CVAC.US): Revenue in Q1 2025 was $939,090, previous value was $13.364 million, expected value was $3.34 million; earnings per share was -$0.24, previous value was -$0.33, expected value was -$0.16.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.